Skip to main content

Table 4 Cumulative fraction of response for various drug regimens against Acinetobacter spp. MICs collected from the Merck ICU Surveillance Study Program (ISS), in four time intervals.

From: A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004

Antimicrobial agent:

CFRa (%)

Time interval:

1993–1995b

1996–1998

1999–2001

2002–2004

p-value

Imipenem 500 mg q6h

94.5

91.5

84.8

84.6

<.0001

Imipenem 1 g q8h

94.2

92.0

86.2

86.1

<.0001

Ceftriaxone 1 g q24h

2.4

1.8

1.9

1.9

.1651

Ceftriaxone 2 g q24h

6.7

5.1

5.2

4.9

.0005

Cefepime 1 g q12h

-

50.8

45.2

35.4

<.0001

Cefepime 2 g q12h

-

65.8

63.1

49.7

<.0001

Cefepime 2 g q8h

-

78.5

80.3

64.4

<.0001

Pip-Tazo 3.375 g q6h

-

56.4

51.3

43.6

<.0001

Pip-Tazo 4.5 g q8h

-

51.9

47.4

40.5

<.0001

Pip-Tazo 4.5 g q6h

-

61.0

55.3

46.6

<.0001

  1. aCFRs were calculated at 40% f T>MIC for imipenem and 50% f T>MIC for the other compounds.
  2. bNo data for cefepime or pip-tazo was provided for 1993–1995.
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us